Insmed Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Insmed kazanç ve gelirin sırasıyla yıllık 66.4% ve 33.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 66.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -68.9% olacağı tahmin edilmektedir.
Anahtar bilgiler
66.4%
Kazanç büyüme oranı
66.17%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 25.2% |
| Gelir büyüme oranı | 33.4% |
| Gelecekteki özkaynak getirisi | -68.95% |
| Analist kapsamı | Good |
| Son güncelleme | 13 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Yeni Anlatı • May 13
Future Respiratory Breakthroughs And Pipeline Expansion Will Transform Long Term Earnings Power
Catalysts About Insmed Insmed focuses on developing and commercializing therapies for serious respiratory and rare diseases. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • May 11
Insmed Incorporated (NASDAQ:INSM) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Shareholders in Insmed Incorporated ( NASDAQ:INSM ) had a terrible week, as shares crashed 28% to US$101 in the week...
Anlatı Güncellemesi • Apr 22
INSM: 2026 Respiratory Launch Execution Will Shape Bronchiectasis Leadership Trajectory
Insmed's updated analyst price target edges down by about $2 to $212.50, as analysts weigh slightly higher discount rate assumptions against continued strong expectations for Brinsupri and the broader respiratory pipeline, as reflected in a series of recent target revisions and new bullish initiations. Analyst Commentary Recent research has been active around Insmed, with several firms updating targets and views following Brinsupri launch commentary, ENCORE data, and management guidance.Anlatı Güncellemesi • Apr 06
INSM: 2026 Respiratory Launch Execution Will Drive Bronchiectasis Market Expansion
Analysts have nudged Insmed's fair value estimate higher to $214.32, reflecting a series of recent price target increases that are tied to confidence in the Brinsupri launch, an expanded bronchiectasis opportunity, and updated Street research on the company's broader respiratory portfolio. Analyst Commentary Recent Street research around Insmed clusters around a few common themes, with most attention on Brinsupri execution, the bronchiectasis market opportunity, and updated revenue guidance through 2026.Seeking Alpha • Apr 01
Insmed: The Pipeline Is Catching Up To The Valuation
Summary Insmed remains a Buy, with enterprise value near $30B and robust growth driven by Brinsupri and pipeline assets. Brinsupri's launch exceeded expectations, with Q4 revenues of $144.6M and management guiding for $1B in 2026 sales. TPIP offers differentiation in PAH/PH-ILD with once-daily dosing and encouraging Phase 2b data, supporting a $3B rNPV estimate. Despite ongoing cash burn, INSM's strong balance sheet and strategic R&D investments position it for continued upside and potential acquisition interest. Read the full article on Seeking AlphaAnlatı Güncellemesi • Mar 20
INSM: 2026 Respiratory Revenue Milestone And Market Expansion Will Drive Platform Potential
Analysts have made a modest upward adjustment to the Insmed price target, increasing the estimated fair value from about $212.53 to $213. They cite renewed confidence in Brinsupri's launch potential, reinforced 2026 guidance and broader bronchiectasis market opportunities highlighted across recent research from Jefferies, BofA, Mizuho, Morgan Stanley, Wells Fargo, Stifel, UBS, Barclays, Roth and RBC.Anlatı Güncellemesi • Mar 05
INSM: Brinsupri Launch And 2026 Revenue Milestone Will Support Future Platform Expansion
Analysts have trimmed their average price target on Insmed by a few dollars to about $213, as slightly higher discount rates and more measured revenue and margin assumptions offset continued optimism around the Brinsupri launch and its longer term market opportunity. Analyst Commentary Recent Street commentary on Insmed clusters around the same core themes, with valuation tweaks mainly driven by updated assumptions on Brinsupri, management's long range guidance, and broader biotech sector conditions.Anlatı Güncellemesi • Feb 18
INSM: European Respiratory Approval And NASDAQ Inclusion Will Support Future Platform Expansion
Narrative Update: Insmed Analyst Price Target Shift Insmed's blended analyst price target edges down by about $1 to roughly $214 as analysts balance slightly lower long term growth and P/E assumptions with ongoing support for the pipeline and recent target changes across the Street. Analyst Commentary Street research on Insmed over recent months shows a cluster of bullish initiations and target moves, with a few more cautious tweaks at the margin.Anlatı Güncellemesi • Feb 04
INSM: European Respiratory Progress And NASDAQ Inclusion Will Support Future Platform Expansion
Analysts have nudged their blended price target for Insmed higher to about $215 per share, reflecting slightly stronger revenue and margin assumptions and a lower future P/E following recent initiation and target updates across the Street. Analyst Commentary Bullish analysts are leaning into Insmed's updated pricing and P/E framework, pointing to specific pipeline and sector factors that they see as supporting the higher blended price target, while more cautious voices are focusing on funding needs and competitive pressures across biotech.Anlatı Güncellemesi • Jan 20
INSM: European Respiratory Portfolio Momentum Will Support Future Platform Expansion
Analysts have nudged their blended price expectations for Insmed slightly lower, trimming the implied fair value by about US$1.60 to reflect modestly higher discount rates, even as they factor in stronger projected revenue growth, wider profit margins and a lower assumed future P/E multiple. This view is supported by recent research highlighting both sector wide M&A potential and company specific drivers such as Brinsupri's EC approval, Q3 execution and anticipated respiratory portfolio expansion.Anlatı Güncellemesi • Jan 06
INSM: European Bronchiectasis Approval Will Support Future Respiratory Platform Expansion
Analysts now place Insmed's blended price target at about US$215.56, edging up from roughly US$214.78 as they factor in recent target moves across the Street tied to Brinsupri's EC approval, Q3 execution, and the broader biotech funding backdrop. Analyst Commentary Bullish Takeaways Bullish analysts highlight Brinsupri's formal EC approval for certain non cystic fibrosis bronchiectasis patients and planned early 2026 access, which they see as an important driver underpinning higher valuation targets above US$210.Anlatı Güncellemesi • Dec 22
INSM: European Bronchiectasis Launch Will Drive Future Respiratory Platform Upside
Insmed's analyst price target has been lifted by about $8 to roughly $215, as analysts factor in strong Brinsupri momentum, expanding indications, and solid execution across the broader respiratory pipeline. Analyst Commentary Bullish analysts continue to lift their models as Brinsupri's early momentum and label breadth in non cystic fibrosis bronchiectasis reshape expectations for Insmed's long term revenue trajectory and margin expansion.Anlatı Güncellemesi • Dec 08
INSM: Respiratory Portfolio Execution And European Expansion Will Shape Future Outlook
Analysts have modestly lifted their price target on Insmed from $214 to $223, reflecting stronger confidence in Brinsupri's European launch trajectory, the expansion of non cystic fibrosis bronchiectasis indications, and continued evidence of robust execution across the broader respiratory portfolio. Analyst Commentary Recent Street research continues to skew positive, with multiple bullish analysts lifting price targets in response to stronger than expected commercial execution and an expanding opportunity set around Brinsupri and the broader respiratory platform.Anlatı Güncellemesi • Nov 24
INSM: Commercial Execution And Pipeline Progress Will Shape Balanced Outlook
Analysts have raised their price target for Insmed from $204.50 to $214.12, citing strong commercial performance, positive product launches, and greater confidence in the company's revenue growth prospects, even as profitability and valuation metrics continue to evolve. Analyst Commentary Analysts covering Insmed have provided a range of perspectives following recent product launches and clinical updates.Anlatı Güncellemesi • Nov 01
INSM: 2025 Launch Will Drive Respiratory Platform Expansion Amid Elevated Expectations
Insmed's analyst price target has climbed significantly, rising by more than $30 to $204.50. Analysts cite stronger pipeline execution, improving profit margins, and expanding growth opportunities across its lead programs as key reasons for the increase.Anlatı Güncellemesi • Oct 17
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Analysts have raised their price target for Insmed, increasing fair value from $164.41 to $172.59. This adjustment is driven by anticipation of broader Brinsupri uptake, pipeline advancements, and improved sentiment following positive clinical and commercial updates.Anlatı Güncellemesi • Oct 03
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Insmed's analyst price target has increased by over $6 to $164.41, as analysts cite stronger revenue growth projections and recent clinical and commercialization achievements as key catalysts for the upward revision. Analyst Commentary Recent analyst activity around Insmed highlights a dynamic mix of optimism and caution, reflecting both the company's clinical progress and commercial prospects.Anlatı Güncellemesi • Sep 07
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Insmed’s consensus price target has increased to $158.00, reflecting analyst optimism around Brinsupri’s broad FDA approval, strong initial commercial outlook, advancing pipeline assets, and positive clinical data, despite some valuation concerns following the recent price appreciation. Analyst Commentary Bullish analysts are raising price targets following the FDA approval of Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis, highlighting a broad label, no major safety warnings, inclusion of FEV1 efficacy data, and a high launch price as key upside surprises that position the therapy for multi-billion dollar opportunities.Anlatı Güncellemesi • Aug 23
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Insmed’s consensus price target has surged to $148.44, driven by the FDA approval and strong commercial prospects for Brinsupri, expanded pipeline potential, and robust Phase 2 results for TPIP—underscoring significant upward revisions in revenue and profit expectations. Analyst Commentary Bullish analysts are raising price targets following FDA approval of Brinsupri as the first therapy for non-cystic fibrosis bronchiectasis, citing a broad label with both doses approved, clean safety profile, and inclusion of favorable FEV1 and secondary endpoint data in prescribing information.Anlatı Güncellemesi • Aug 08
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Despite a sharply higher future P/E and a substantial decline in net profit margin, analysts have aggressively raised Insmed’s price target from $68.64 to $120.12. What's in the News Insmed reported positive topline Phase 2b results for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension, meeting primary and all secondary endpoints.Analiz Makalesi • Jun 11
Insmed Incorporated's (NASDAQ:INSM) Shares Climb 40% But Its Business Is Yet to Catch Up
Insmed Incorporated ( NASDAQ:INSM ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Apr 25
Insmed: Poised For Transformation Beyond ARIKAYCE
Summary Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 results for non-cystic fibrosis bronchiectasis, with a potential FDA approval by August 2025, highlighting a significant market opportunity. Insmed's diversified pipeline, including TPIP and INS1201, reduces reliance on a single product and enhances long-term growth prospects. Despite financial risks, INSM's $1.4 billion cash reserve and potential multi-billion dollar market opportunities make it a compelling investment for those with a high-risk tolerance. Read the full article on Seeking Alpha
Yeni Anlatı • Mar 19
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Anticipated U.S. and international launches of brensocatib are key catalysts for significant revenue growth and new market penetration.Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 3,852 | 853 | 813 | 958 | 17 |
| 12/31/2027 | 2,794 | 113 | 45 | 230 | 19 |
| 12/31/2026 | 1,701 | -566 | -418 | -406 | 19 |
| 3/31/2026 | 820 | -1,184 | -967 | -896 | N/A |
| 12/31/2025 | 606 | -1,277 | -998 | -935 | N/A |
| 9/30/2025 | 447 | -1,184 | -906 | -883 | N/A |
| 6/30/2025 | 398 | -1,034 | -869 | -845 | N/A |
| 3/31/2025 | 381 | -1,013 | -789 | -762 | N/A |
| 12/31/2024 | 364 | -914 | -706 | -684 | N/A |
| 9/30/2024 | 343 | -864 | -636 | -619 | N/A |
| 6/30/2024 | 329 | -803 | -591 | -574 | N/A |
| 3/31/2024 | 315 | -747 | -589 | -574 | N/A |
| 12/31/2023 | 305 | -750 | -550 | -536 | N/A |
| 9/30/2023 | 281 | -724 | -524 | -509 | N/A |
| 6/30/2023 | 269 | -696 | -476 | -462 | N/A |
| 3/31/2023 | 257 | -547 | -453 | -442 | N/A |
| 12/31/2022 | 245 | -482 | -410 | -400 | N/A |
| 9/30/2022 | 242 | -434 | -388 | -381 | N/A |
| 6/30/2022 | 221 | -416 | -374 | -367 | N/A |
| 3/31/2022 | 201 | -438 | -348 | -340 | N/A |
| 12/31/2021 | 188 | -435 | -371 | -363 | N/A |
| 9/30/2021 | 174 | -424 | -354 | -346 | N/A |
| 6/30/2021 | 171 | -375 | -336 | -329 | N/A |
| 3/31/2021 | 168 | -319 | -295 | -290 | N/A |
| 12/31/2020 | 164 | -294 | -226 | -219 | N/A |
| 9/30/2020 | 169 | -245 | -215 | -197 | N/A |
| 6/30/2020 | 164 | -242 | -223 | -191 | N/A |
| 3/31/2020 | 151 | -247 | -276 | -235 | N/A |
| 12/31/2019 | 136 | -254 | N/A | -251 | N/A |
| 9/30/2019 | 101 | -293 | N/A | -276 | N/A |
| 6/30/2019 | 62 | -320 | N/A | -290 | N/A |
| 3/31/2019 | 32 | -330 | N/A | -264 | N/A |
| 12/31/2018 | 10 | -324 | N/A | -258 | N/A |
| 9/30/2018 | N/A | -298 | N/A | -236 | N/A |
| 6/30/2018 | N/A | -256 | N/A | -209 | N/A |
| 3/31/2018 | N/A | -224 | N/A | -190 | N/A |
| 12/31/2017 | N/A | -193 | N/A | -160 | N/A |
| 9/30/2017 | N/A | -196 | N/A | -169 | N/A |
| 6/30/2017 | N/A | -188 | N/A | -162 | N/A |
| 3/31/2017 | N/A | -180 | N/A | -154 | N/A |
| 12/31/2016 | N/A | -176 | N/A | -147 | N/A |
| 9/30/2016 | N/A | -139 | N/A | -116 | N/A |
| 6/30/2016 | N/A | -132 | N/A | -109 | N/A |
| 3/31/2016 | N/A | -124 | N/A | -105 | N/A |
| 12/31/2015 | N/A | -118 | N/A | -101 | N/A |
| 9/30/2015 | N/A | -105 | N/A | -86 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: INSM önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: INSM önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: INSM önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: INSM şirketinin gelirinin (yıllık 33.4% ) US pazarından (yıllık 11.7% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: INSM şirketinin gelirinin (yıllık 33.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: INSM 3 yıl içinde kârsız olması bekleniyor.
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/16 20:07 |
| Gün Sonu Hisse Fiyatı | 2026/05/15 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Insmed Incorporated 42 Bu analistlerden 19, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Neena Bitritto-Garg | Baird |
| Eliana Merle | Barclays |
| Anita Dushyanth | Berenberg |